Table 1.
Participant clinical, radiological, and CMR characteristics
| Clinical characteristics | Age- and sex-matched controls (n = 13) | Aortic stenosis (n = 22) | Amyloid (n = 18) |
|---|---|---|---|
| Age | 65 ± 15 | 76 ± 8 | 70 ± 9 |
| Male | 8/13 (62%) | 15/22 (68%) | 14/18 (78%) |
| BMI (kg/m2) | 26.0 ± 3.0 | 28.6 ± 4.2 | 24.4 ± 5.1 |
| Smoking (ex or current) | 3/13(23%) | 9/22 (41%) | 8/18 (44%) |
| Hypertension | 4/13 (31%) | 13/22 (59%) | 11/18 (61%) |
| Hyperlipidaemia | 4/13 (31%) | 11/22 (50%) | 8/18 (44%) |
| Diabetes | 1/13 (8%) | 4/22 (18%) | 5/18 (28%) |
| Previous myocardial Infarction | 0/13 (0%) | 2/22 (9%) | 2/18 (11%) |
| Previous PCI | 0/13(0%) | 3/22 (14%) | 3/18 (17%) |
| Imaged in Edinburgh | 6 | 22 | 5 |
| Administered dose 18F-Fluoride (MBq) | 308 ± 80 | 201 ± 58 | 333 ± 91 |
| PET/MR injection-to-scan interval (mins) | 50 ± 18 | 80 ± 31 | 55 ± 22 |
|
Body surface area (m2) |
1.91 ± 0.20 | 1.96 ± 0.17 | 1.86 ± 0.26 |
| LVEDi | 72 ± 20 | 76 ± 24 | 72 ± 21 |
| LVESVi | 18 ± 5 | 26 ± 23 | 31 ± 25 |
| LVSVi | 55 ± 17 | 52 ± 11 | 40 ± 11 |
| Ejection Fraction (%) | 75 ± 6 | 70 ± 17 | 60 ± 18 |
| LVMi | 64 ± 8 | 100 ± 26 | 101 ± 36 |
BMI, body mass index; PCI, percutaneous coronary intervention; PET/MR, positron emission tomography/magnetic resonance; CMR, cardiac magnetic resonance; LVEDi, left ventricular end diastolic volume indexed; LVESVi, left ventricular end systolic volume indexed; LVSVi, left ventricular stroke volume indexed; LVMi, left ventricular mass indexed